Cantor Fitzgerald Reiterates “Overweight” Rating for Structure Therapeutics (NASDAQ:GPCR)

Cantor Fitzgerald restated their overweight rating on shares of Structure Therapeutics (NASDAQ:GPCR) in a research report report published on Monday, Benzinga reports. Cantor Fitzgerald currently has a $65.00 price target on the stock.

Several other analysts have also recently weighed in on the company. BMO Capital Markets lifted their price objective on Structure Therapeutics from $83.00 to $100.00 and gave the company an outperform rating in a research report on Friday, June 7th. JPMorgan Chase & Co. initiated coverage on Structure Therapeutics in a research report on Tuesday, May 21st. They set an overweight rating and a $65.00 price objective on the stock. Finally, JMP Securities cut their price objective on Structure Therapeutics from $91.00 to $86.00 and set a market outperform rating on the stock in a research report on Friday, August 9th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Structure Therapeutics has a consensus rating of Buy and an average price target of $84.63.

Structure Therapeutics Price Performance

NASDAQ GPCR opened at $39.64 on Monday. The stock has a market capitalization of $1.85 billion, a PE ratio of -51.48 and a beta of -3.52. Structure Therapeutics has a 1 year low of $26.61 and a 1 year high of $75.02. The business’s 50-day moving average is $38.01 and its 200 day moving average is $39.72.

Structure Therapeutics (NASDAQ:GPCR) last posted its earnings results on Thursday, August 8th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.05. As a group, equities research analysts anticipate that Structure Therapeutics will post -0.86 earnings per share for the current year.

Hedge Funds Weigh In On Structure Therapeutics

Several large investors have recently made changes to their positions in the business. Teachers Retirement System of The State of Kentucky lifted its holdings in shares of Structure Therapeutics by 28.5% during the second quarter. Teachers Retirement System of The State of Kentucky now owns 17,651 shares of the company’s stock valued at $693,000 after purchasing an additional 3,918 shares during the last quarter. Perceptive Advisors LLC purchased a new position in shares of Structure Therapeutics during the second quarter valued at approximately $1,369,000. Quarry LP purchased a new position in Structure Therapeutics in the 2nd quarter worth approximately $79,000. Driehaus Capital Management LLC raised its holdings in Structure Therapeutics by 3.5% in the 2nd quarter. Driehaus Capital Management LLC now owns 2,577,136 shares of the company’s stock worth $101,204,000 after acquiring an additional 86,833 shares during the last quarter. Finally, Blue Owl Capital Holdings LP purchased a new position in Structure Therapeutics in the 2nd quarter worth approximately $2,160,000. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.